Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Daratumumab in Thigh vs Abdomen for Plasma Cell Disorders
NCT07075510Phase 2Recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Oct 2025
- Primary completion
- Oct 2030
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), amyloidosis, sponsored by University of Maryland, Baltimore. Started Oct 2025; status: recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)amyloidosis
Beyond the preview
Go deeper on NCT07075510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07075510.